Methadone Maintenance System Performance Measures – 2011/2012 Office of the Provincial Health Officer January 28, 2013 1 Dr. Eric Young, MD, MHSc, CCFP,

Slides:



Advertisements
Similar presentations
Common/shared responsibilities between jobs.
Advertisements

Delphine Sculier, MD,MPH Stop TB Department World Health Organisation Geneva, Switzerland Update on the revision of ART guidelines for TB patients.
RATIONAL USE OF INJECTION: An Integrated Tool For Monitoring Injection Prescription in the Kingdom of CAMBODIA Dr Sok Srun Department of Hospitals, MoH.
Revalidation of Licensure Douglas H. Blackman, MD, CCFP Deputy Registrar College of Physicians & Surgeons of BC May 12, 2008.
Electronic Prescribing in BC: The Past, The Present, and The Future February 19, 2015 Quality Forum 2015 Sorin Pop, BC Ministry of Health 1.
Walsall Healthcare NHS Trust Medicines Management.
Title: PEOPLE LIVING WITH HIV/AIDSIN EGYPT: ROLE OF COMMUNITY PHARMACIST Authors: Nahla Maher Hegab Pharmacy graduate. Institution: College of pharmacy,
1 Potential & Actual Opioid Diversion in Vietnam, Methods of Preventing Diversion, and Barriers to “Balance” Eric Krakauer, MD, PhD Harvard Medical School.
MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy Kevin S. Flanigan, MD Medical Director Office of MaineCare.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Drug Utilization Review (DUR)
A Pharmacist’s journey: the development of targeted opportunistic multi-disciplinary team training in the treatment of opioid dependence Kevin Foreman.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Rankings: What do they matter, what do they measure? Anne McFarlane August 18, 2010.
MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.
Dr. Yogan Pillay Deputy Director General National Department of Health, South Africa Monday 1 July 2013 OPERATIONAL AND PROGRAMMATIC CONSIDERATIONS IN.
Anne Burns, RPh Group Director, Practice Development and Research
Application of an International Reference Price List to National Medicines Procurement Tenders Bada Pharasi, Gavin Steel, Jean-Pierre Sallet, SPS, Management.
.  Introduction to Methadone Maintenance Therapy (MMT)  Introduction to Harm Reduction  Benefits of MMT  One Patient’s Perspective  Misconceptions.
Engaging the C-suite to Advance Pharmacy Practice Providing quality patient care through progressive pharmacy practice Evaluation of Unit-based Pharmacy.
Setting the Context: The BC Health System Andrew Wray – April 8, 2013.
STOP HIV/AIDS Rolando Barrios, MD, FRCPC Assistant Director BC Centre for Excellence in HIV/AIDS Assistant Medical Director HIV/AIDS Program Providence.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
OPIOID SUBSTITUTION THERAPY
Power B, McQuoid P, Caldwell NA, Clareburt A. Pharmacy Department, Wirral Hospital NHS Trust, Wirral. Poster Layout & Design By Wirral Medical Illustration.
Florida Agency for Health Care Administration Florida Center for Health Information and Policy Analysis Florida Public Health Association - Medical Director’s.
Rational Prescribing & Prescription Writing Collected and Prepared By S.Bohlooli, Pharm.D, PhD.
For Pain or Not for Pain: Methadone Madness
Slide 1 of 42 IAS–USA AU EDITED FINAL: Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director,
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
Methadone ? Methadone and Treatment By: Eleu Pontes CSW.
Physicians’ Attitudes to Methadone Maintenance Treatment in Nova Scotia Jessica Dooley*, M.Sc. Candidate Dr. Susan Kirkland*, Ph. D. Dr. Mark Asbridge*,
San Francisco County OBOT Pilot: Pharmacy Aspects Sharon Kotabe, PharmD Associate Administrator for Pharmaceutical Services Associate Clinical Professor.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
What Does Research Tell Us? Care Manager Roles in Depression Care.
Abstract ID: 395 Author Name: Araya Sripairoj Presenter Name: Araya Sripairoj Authors: Sripairoj A, Liamputtong P, Harvey K.
Medication Error Reduction Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Abstract Impact of the Essential Drugs Programme at the Primary Health Care Level in South Africa Hela M, Zeeman H, Department of Health South Africa;
Sebastian Schneeweiss, M.D., Sc.D. Instructor in Medicine and Epidemiology Director for Policy Studies Division of Pharmacoepidemiology and Pharmacoeconomics.
Trends in Opioid Use and Overdose in BC: Making the case for greater availability of Take Home Naloxone programs Ashraf Amlani Harm Reduction Epidemiologist.
“USAPI-PHARMACY ASSOCIATION - RESPONSE TO NCD ROADMAP” Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa 51 st 1-18 nov 2011 Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa.
Preventing Errors in Medicine
Accutane FDA (Section Name - Saver’s Initials) 3/9/00 12:50 PM 1 Risk Management Options Russell Ellison, MD Chief Medical Officer Vice President, Medical.
Bringing Hepatitis C Treatment into the Medical Home A Pilot Program for Drug Users Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission.
DOES DRUG USE EVALUATION (DUE) REQUIRED BY NATIONAL POLICY IMPROVE USE OF MEDICINES?
Does Drug Use Evaluation Required by National Policy Improve Use of Medicines? Akaleephan C*, Muenpa R**, Sittitanyakit B***, Treesak C #, Cheawchanwattana.
Developing role of community pharmacy in responding to the needs of people with drug problems Karen Melville Principal Pharmacist TSMS NHS Tayside.
Expanding the Reach of Evidence in Nova Scotia Can we get the Evidence to Everyone? CADTH Symposium 2016 Lisa Farrell- Chair of DEANS ( NS Liaison CADTH)
Documentation in Practice Dept. of Clinical Pharmacy.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medication Assisted Treatment
Wireless Access SSID: cwag2017
Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Medication-Assisted Therapy at Coleman Profession Services
Strategies to Reduce Antibiotic Resistance and to Improve Infection Control Robin Oliver, M.D., CPE.
Community Hospital Pharmacy Practice January 29, 2004
PHARMACY 2012: ADDING VALUE TO THE HEALTHCARE SYSTEM
San Francisco County OBOT Pilot: Pharmacy Aspects
ESCP 2017 Workshop, Leiden, the Netherlands, June
Introduction to Clinical Pharmacy
Opioids – A Pharmaceutical Perspective on Prescription Drugs
CHAPTER 4 Information Management in Pharmacy.
The three components of patient self-care
Hospital Antibiotic Stewardship Programs
Pharmacy practice experience I
Sabaydee.
HIV.
Introduction Project At Crown Street Surgery:
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Methadone Maintenance System Performance Measures – 2011/2012 Office of the Provincial Health Officer January 28, Dr. Eric Young, MD, MHSc, CCFP, FRCPC Deputy Provincial Health Officer

Background  2002 Health Canada Best Practices – PMMT  2009 BCMA – Policy Paper on Addictions  2009 independent review of BC’s methadone maintenance system (CARBC & UBC’s CHEOS) “Methadone Maintenance Treatment in British Columbia, : Analysis and Recommendations” (September 2010)  Government response  PHO follow-up monitoring of MMT key indicators (not including data on-reserve First Nations) 2

3

HMHP Key actions and outcomes related to BC’s Methadone Maintenance System  p Enhance and improve BC’s methadone maintenance treatment system (including medical, pharmaceutical and psychosocial support components)  p. 34 – By 2015: a)90 per cent of methadone prescribers will adhere to optimal dose guidelines b)60 per cent of people started MMT retained at 12 months  p. 23 – Where appropriate, expand the reach and range of harm-reduction services that prevent and reduce the health, social and fiscal impacts of illegal drug use 4

Introduction  Effectiveness of the province’s MMS involves three key components: o prescribing o dispensing o counselling and other adjunct services and supports  Regulatory Bodies o College of Physicians and Surgeons of BC o College of Pharmacists of BC 5

MMS Measures  The reach of BC’s MMS can be summarized by reporting on key professional participation indicators o # of patients with methadone maintenance prescriptions (whose meds covered by PharmaCare) o # of physician prescribers o # of methadone-dispensing pharmacists and pharmacies 6

Methadone Maintenance Patients by Health Authority 7

New Methadone Maintenance Patients by Health Authority 8

Methadone Maintenance Active Prescribers by Health Authority 9

Methadone Maintenance Pharmacies by Health Authority 10

System Outcome Measures  Retention on Rx  Hospitalizations (all cause)  Mortality (all cause) 11

Percentage of patients started on MMT retained at 12 months 12

Effect of daily dose on methadone maintenance treatment retention 13

Adherence to minimum effective stabilization dose guideline 14

Hospitalizations per 100 Person Years During MMT 15

All-cause Mortality During Methadone Maintenance Treatment 16

Conclusion MMT – significant growth over the past decade > access to MMT and other harm reduction initiatives  lower incidence HIV infection among people who inject drugs There are areas of the system where progress is stagnant or reversing! Solutions - needed 17